{"id":493108,"date":"2021-05-13T09:03:55","date_gmt":"2021-05-13T13:03:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/"},"modified":"2021-05-13T09:03:55","modified_gmt":"2021-05-13T13:03:55","slug":"lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/","title":{"rendered":"Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit"},"content":{"rendered":"
\n

AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) — Lumos Pharma, Inc.<\/a>\u00a0(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 and will be hosting virtual one-on-one meetings with investors throughout the day.<\/p>\n\n\n\n\n
\u00a0<\/td>\nEvent:<\/td>\n\u00a0<\/td>\n\n Oppenheimer Rare & Orphan Disease Summit<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\nDate:<\/td>\n\u00a0<\/td>\nMay 21, 2021<\/td>\n<\/tr>\n
\u00a0<\/td>\nTime:<\/td>\n\u00a0<\/td>\nLive Presentation 10:45 AM \u2013 11:25 AM (ET)<\/td>\n<\/tr>\n<\/table>\n

The live Lumos Pharma presentation can be accessed through the link Oppenheimer Rare & Orphan Disease Summit (wsw.com)<\/a>. The link can also be found on the Company\u2019s website under \u201cEvents & Presentations<\/a>\u201d in the Investors & Media section where a replay will be available for 90 days. Please contact your Oppenheimer salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team during the Summit or thereafter.<\/p>\n

\n About Lumos Pharma<\/strong>\n <\/p>\n

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Sant\u00e9 Ventures, and UCB. Lumos Pharma\u2019s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2b clinical trial, the OraGrowtH210 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit https:\/\/lumos-pharma.com\/<\/a>.<\/p>\n

Investor & Media Contact:<\/p>\n

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com<\/a><\/p>\n

Source: Lumos Pharma, Inc.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) — Lumos Pharma, Inc.\u00a0(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 and will be hosting virtual one-on-one meetings with investors throughout the day. \u00a0 Event: \u00a0 Oppenheimer Rare & Orphan Disease Summit \u00a0 Date: \u00a0 May 21, 2021 \u00a0 Time: \u00a0 Live Presentation 10:45 AM \u2013 11:25 AM (ET) The live Lumos Pharma presentation can be accessed through the link Oppenheimer Rare & Orphan Disease Summit (wsw.com). The link can also be found on the Company\u2019s website under \u201cEvents & Presentations\u201d in the Investors & Media section where a replay … <\/p>\n

Continue reading “Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-493108","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) — Lumos Pharma, Inc.\u00a0(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 and will be hosting virtual one-on-one meetings with investors throughout the day. \u00a0 Event: \u00a0 Oppenheimer Rare & Orphan Disease Summit \u00a0 Date: \u00a0 May 21, 2021 \u00a0 Time: \u00a0 Live Presentation 10:45 AM \u2013 11:25 AM (ET) The live Lumos Pharma presentation can be accessed through the link Oppenheimer Rare & Orphan Disease Summit (wsw.com). The link can also be found on the Company\u2019s website under \u201cEvents & Presentations\u201d in the Investors & Media section where a replay … Continue reading "Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-13T13:03:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTY2MiM0MTgxMTE3IzIwMTY1Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit\",\"datePublished\":\"2021-05-13T13:03:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\\\/\"},\"wordCount\":319,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTY2MiM0MTgxMTE3IzIwMTY1Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\\\/\",\"name\":\"Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTY2MiM0MTgxMTE3IzIwMTY1Nzc=\",\"datePublished\":\"2021-05-13T13:03:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTY2MiM0MTgxMTE3IzIwMTY1Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTY2MiM0MTgxMTE3IzIwMTY1Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/","og_locale":"en_US","og_type":"article","og_title":"Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit - Market Newsdesk","og_description":"AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) — Lumos Pharma, Inc.\u00a0(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 and will be hosting virtual one-on-one meetings with investors throughout the day. \u00a0 Event: \u00a0 Oppenheimer Rare & Orphan Disease Summit \u00a0 Date: \u00a0 May 21, 2021 \u00a0 Time: \u00a0 Live Presentation 10:45 AM \u2013 11:25 AM (ET) The live Lumos Pharma presentation can be accessed through the link Oppenheimer Rare & Orphan Disease Summit (wsw.com). The link can also be found on the Company\u2019s website under \u201cEvents & Presentations\u201d in the Investors & Media section where a replay … Continue reading \"Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-13T13:03:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTY2MiM0MTgxMTE3IzIwMTY1Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit","datePublished":"2021-05-13T13:03:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/"},"wordCount":319,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTY2MiM0MTgxMTE3IzIwMTY1Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/","name":"Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTY2MiM0MTgxMTE3IzIwMTY1Nzc=","datePublished":"2021-05-13T13:03:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTY2MiM0MTgxMTE3IzIwMTY1Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTY2MiM0MTgxMTE3IzIwMTY1Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-the-oppenheimer-rare-orphan-disease-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/493108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=493108"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/493108\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=493108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=493108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=493108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}